Prediction of Responsiveness to Clomiphene Citrate in Infertile Women with PCOS.
Polycystic ovary syndrome (PCOS) is a common problem in patients dealing with infertility (1). With increasing modernization, its prevalence is growing rapidly. PCOS falls in the category ofWHOtype II anovulation (norm-gonaddotrophic norm-estrogenic anovulation) and accounts for 85% of anovulatory females (2).
Clomiphene citrate is a triphenylethylene derivative which acts as an estrogen antagonist. It causes an increase in the release of gonadotropins from pituitary by blocking the negative feedback of estrogen and helps in the recruitment of the follicles (3). Clomiphene citrate (CC) is a drug that has been used for several years for combating PCOS related infertility (4). However, there is still an enigma as to why some PCOS women respond to the treatment while others do not. The preva-lence of clomiphene resistance is as high as 15-40% (5).
Hyperandrogenism, obesity, insulin resistance, metabolic syndrome, and other endocrine abnormalities are proven associations or results of PCOS (6). But whether these factors also predict response to treatment in women with PCOS related infertility is still a dilemma. If the answer to this is yes, then the strength of these factors' influence on the response is another question.
The study by Wenyan et al. (7) found AMH to be a significant predictor of non-responsiveness to clomiphene. Also, the study by Hamed et al. (8) demonstrated the role of patient's BMI, testosterone, anti-mullerian hormone and ovarian volume in predicting response to clomiphene citrate treatment. A study by Johnson et al. (9) revealed BMI to be a predictor of response to ovulation induction agents. These studies give limited evidence about the factors influencing the response to clomiphene.
So, an attempt was made to analyze various clinical, metabolic, hormonal, and ultrasound parameters in predicting the response to clomiphene. Once predictors of ovarian responsiveness or nonresponsiveness are found, a more specific treatment to our patients can be given. This will not only save the overall cost but will also save the precious time of our patients who come to us with a lot of hope.
This prospective observational study enrolled 164 patients with PCOS related infertility from the infertility Out Patient Department (OPD) of a government hospital over the period of one year.
The study included infertile women with PCOS (based on Rotterdam's criteria (10)) in age group of 18-40 years. Women on any insulin-sensitizing agent or lipid-lowering agent or even those having an endocrine disorder or anorexia nervosa/bulimia nervosa or with hypothalamic or pituitary dysfunction were excluded from this study.
All PCOS women desirous of pregnancy were evaluated only after taking a written informed consent. Relevant history was taken to rule out the exclusion criteria. The physical examination included blood pressure, weight in kilograms using a beam balance and height in upright posture without shoes using a stadiometer (to the nearest 0.5 cm was recorded). BMI was recorded based on the above measurements. Owing to the differences in body fat distribution between Asian and Western population, WHO expert committee in 2004 (11) has proposed BMI cut-offs for the Asian population which has been used in this study.
Waist circumference (WC) was measured midway between lower rib margin and the iliac crest in the mid-axillary line at the end of normal expiration (12). Hip circumference was measured with the measuring tape at the highest prominence of the buttocks and parallel to the floor (12). Waist and hip circumference were recorded after removing clothing from the area over waist and hip. The cut-off value of BMI was <23 kg/[m.sup.2], and for waist circumference was 80 cm, and for the waist-hip ratio (WHR), the value turned out to be 0.81 based on the study conducted among the Asians (12).
Thyroid gland was examined for any enlargement, nodules or tenderness. The breast was examined for its characteristics and secretions. Signs of androgen excess like excessive hair growth, acne or alopecia were looked for. Excessive hair growth was evaluated by modified Ferriman and Gallwey (13) (FG) score.
The patients enrolled in the study were called on day 2 of their subsequent cycle for the investigations (FSH, LH, AMH, 17-hydroxyprogesterone levels (17 OHP), testosterone, androstenedione, 75 gm oral glucose tolerance test (OGTT), fasting insulin, fasting triglycerides, HDL (high density lipoprotein), LDL (low density lipoprotein), and cholesterol levels). Abdominal ultrasound was also done to rule out the fatty changes in the liver. The homeostasis model assessment of insulin resistance (HOMA-IR) (14), a surrogate marker of insulin resistance, was used in this study. Patients with HOMA-IR >2 were defined as having insulin resistance.
Baseline transvaginal scan (TVS) was done by the same observer using a Philips ultrasound machine, model IU22 (TVS probe frequency ranges 5-7 MHZ). Ovarian volume of each ovary was assessed by ellipsoid formula i.e. 0.52 X D1 (longitudinal) X D2 (oblique) X D3 (transverse) diameters. Mean ovarian volume was calculated by adding the volume of both ovaries and then dividing it by 2. Ovarian follicles in each ovary were examined and the total number of the follicles was counted by scanning each ovary from inner to the outer margin in longitudinal cross-section. Mean follicle number was calculated by adding the follicles of both ovaries and then dividing it by 2.
All these patients were treated with clomiphene citrate starting with 50 mg/day on day 2-5 of their cycle for 5 days. In case of failure of ovulation, the dose was increased by 50 mg in subsequent cycles to a maximum dose of 150 mg over 3 cycles.
Response to clomiphene citrate was assessed by ovulation. Transvaginal scan (TVS) was done by the same observer using a Philips ultrasound machine, model IU22. A scan was done starting from day 10 of the cycle and until reaching follicle size >18 mm or day 20 of the cycle. Patients were called after 2-3 days of development of dominant follicle to be checked for the rupture of the follicle.
Based on the ovulation pattern, these patients were divided into 2 groups, one who ovulated with maximum dose of 150 mg of clomiphene citrate and others who did not ovulate, as clomiphene citrate-resistant group.
The various parameters were compared between the clomiphene citrate-resistant and clomiphene citrate-sensitive groups.
The various parameters were recorded as Mean[+ or -] SD. Normality of quantitative data was checked by measures of Kolmogorov Smirnov tests of normality and independent t-test or Mann Whitney U test was used based on whether data was normally distributed or not. Univariate and multiple logistic regression were used to study the various predictors of non-responsiveness to clomiphene citrate. Receiver operating characteristic (ROC) curve was used to assess the area under the curve (AUC), sensitivity, and specificity of each predictor. All statistical tests were two-sided and performed at a significance level of [alpha]=0.05. The analysis was conducted using IBM SPSS Statistics (version 24.0).
Ethical consideration: Informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This study enrolled 164 women with PCOS related infertility. Of these, 88 (53.7%) were CC (clomiphene citrate) resistant and 76 (46.3%) were CC-sensitive. Baseline distribution and comparison between clomiphene citrate-resistant and sensitive group are given in table 1.
To establish predictors of non-responsiveness to clomiphene citrate, logistic regression analysis was done.
In univariate regression analysis (Table 2) between CC-resistant and CC-sensitive PCOS women, BMI, waist circumference, Ferriman-Gallwey score, oral glucose tolerance test (OGTT)- fasting/1 hr/ 2 hr values, HOMA-IR, LDL, HDL, triglyceride, cholesterol, androstenedione, AMH, LH-FSH ratio, ovarian volume, and antral follicle count were found to be statistically significant. However, in multivariate logistic regression (Table 3), only Ferriman-Gallwey score, androstenedione levels, HDL and cholesterol were found to be the independent predictor of non-responsiveness to clomiphene citrate.
Statistically significant AUC of each ROC curve in predicting non-response to clomiphene-citrate (CC) is depicted in table 4. The overall best predictor of non-response to clomiphene citrate in this study was Ferriman-Gallwey score with the maximum AUC of ROC curve. If the cut-off value of FG score is taken to be 15, it had 73.9% sensitivity and 86.8% specificity in predicting nonresponsiveness to clomiphene.
When considering the anthropometric parameters (age, weight, height, BMI, waist circumference, and waist-hip ratio), BMI was the best predictor of non-responsiveness to clomiphene with maximum AUC (Figure 1). If the cut-off value of BMI was taken as 25.950, it had 58% sensitivity and 57.9% specificity in predicting non-responsiveness to clomiphene.
Taking into account the parameters of insulin resistance (OGTT values, HOMA-IR, and fasting insulin), fasting insulin was the best predictor of the non-responsiveness to clomiphene. If the cutoff value of fasting insulin was taken as 10.77, it had 67% sensitivity and 67% specificity in predicting non-responsiveness to clomiphene (Figure 2).
Taking into account the parameters used for determining ovarian reserve (mean ovarian volume, mean AFC, and AMH), mean AFC is the best predictor of the non-responsiveness to clomiphene with maximum AUC of the ROC curve (Figure 3) (cut-off value of 11.75 with73.9% sensitivity and 73.7% specificity).
In this study, significant differences were seen in BMI, waist circumference, waist-hip ratio, parameters indicating hyperandrogenism (Ferriman-Gallwey score, testosterone, and androstenedione levels), parameters indicating insulin resistance (deranged oral glucose tolerance test, fasting insu lin, and HOMA-IR), derangements in lipid profile (LDL, HDL, cholesterol, and triglyceride levels), ovarian reserve parameters (AMH, AFC, and ovarian volume), LH levels, and LH-FSH ratio amongst the clomiphene resistant and sensitive groups.
The results of the present study were based on the ovulation trend and not the conception. This is because conception is influenced by various other factors like endocrine dysfunction, tubal or uterine factors or male factors resulting in infertility. Clomiphene and other ovulation inducing agents primarily affect ovulation.
Hyperandrogenism (clinical and biochemical) proved to be a good predictor of clomiphene citrate resistance with high AUC curve value. The parameters for hyperandrogenism used in the study were Ferriman-Gallwey score, serum androstenedione, and testosterone. The study by Hamed et al. (8) and Imani et al. (15) manifested similar results. Increased androgens convert to estrone which causes negative feedback on hypothalamus and pituitary resulting in decreased FSH and anovulation. This is a possible explanation for increased hyperandrogenism which results in clomiphene resistance (16).
AMH, AFC, and ovarian volume are commonly used markers of ovarian reserve in clinical practice. The present study demonstrated higher AUC for AFC followed by mean ovarian volume and then AMH. These results differed from the study conducted by Nardo et al. (17), in which AMH was superior to FSH and AFC in predicting ovarian response. The study by Jayaprakasan et al. (18) also demonstrated that AMH and AFC either alone or in combination are good predictors of ovarian reserve. Also, the study by Wenyan Xi et al. (7) and Mahran et al. (19) found AMH to be a good predictor of clomiphene response. AMH is the hormone produced by primordial and small antral follicles (up to 6-8 mm). High AMH values result in anovulation by inhibiting FSH action and FSH receptor. This is the possible explanation for high AMH and AFC values resulting in poor responsiveness to clomiphene (20). So, in practice, it is always good to know the ovarian reserve of the patients before starting ovulation induction. However, more studies are required to establish the best ovarian reserve marker in predicting response to ovulation induction.
It is a known fact that PCOS is associated with insulin resistance and metabolic disturbances (21). However, no studies have yet been done to associate the metabolic profile of the patients in predicting response to clomiphene. In this study, BMI was a good predictor of non-responsiveness to clomiphene. With a cut-off value of 25.950, it had 58% sensitivity and 57.9% specificity in predicting non-responsiveness to clomiphene. Also, insulin resistance markers (OGTT values, HOMAIR, and fasting insulin) can also help in predicting non-responsiveness to clomiphene. The best marker amongst these was fasting insulin. Hyperinsulinism results in hyperandrogenism by increasing LH induced androgen synthesis and decreasing sex hormone binding globulin (22). This explains increased clomiphene resistance in patients with hyperinsulinism. Also, deranged lipid profile, LDL >100.430 and cholesterol >168.465, had >70% sensitivity and specificity in predicting non-responsiveness to clomiphene. Thus, lifestyle modification and weight loss should always be offered to patients with obesity and metabolic disturbances. Weight loss results in decrease in cholesterol, triglyceride and LDL levels, improvement in insulin resistance, increase in sex hormone binding globulin and decrease in testosterone levels.
Thus, based on this study, it is good to know the baseline hyperandrogenism, ovarian reserve parameters and metabolic profile of the patients before initiating clomiphene treatment. Screening the patients for these factors before starting ovulation induction treatment will help in providing appropriate counseling on the chances of success of treatment. Also, since the patients will save a lot of time and money, the degree of disappointment and frustration will naturally be less. Based on the results of this study, patients with severe hyperandrogenism, high AMH and AFC values and deranged lipid profile and insulin resistance should be given an option of alternative treatment after a short trial of clomiphene.
Conflict of Interest
The authors declare that they have no conflict of interest.
(1.) Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370 (9588): 685-97.
(2.) Broekmans F, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser B. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210-7.
(3.) Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. Cochrane Database Syst Rev. 2000;(2):CD000056.
(4.) Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician. 2009;79(8):671-6.
(5.) Wang L, Qi H, Baker PN, Zhen Q, Zeng Q, Shi R, et al. Altered circulating inflammatory cytokines are associated with anovulatory polycystic ovary syndrome (PCOS) women resistant to clomiphene citrate treatment. Med Sci Monit. 2017;23:1083-9.
(6.) Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstet. 2001;75(1):43-50.
(7.) Xi W, Yang Y, Mao H, Zhao X, Liu M, Fu S. Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome. J Ovarian Res. 2016;9:3.
(8.) Ellakwa HE, Sanad ZF, Hamza HA, Emara MA, Elsayed MA. Predictors of patient responses to ovulation induction with clomiphene citrate in patients with polycystic ovary syndrome experienceing infertility. Int J Gynaecol Obstet. 2016;133(1): 59-63.
(9.) Johnson NP, Bontekoe S, Stewart AW. Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2011;51(3):252-6.
(10.) Rotterdam ESHRE/ASRM-Sponspred PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 200419(1):41-7.
(11.) WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63.
(12.) Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. Eur J Clin Nutr. 2010;64(1):2-5.
(13.) Wild RA, Vesely S, Beebe L, Whitsett T, Owen W. Ferriman gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(7): 4112-4.
(14.) Ray S, Bairagi AK, Guha S, Ganguly S, Ray D, Basu AK, et al. A simple way to identify insulin resistance in non-diabetic acute coronary syndrome patients with impaired fasting glucose. Indian J Endocrinol Metab. 2012;16(Suppl 2):S460-4.
(15.) Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83(7): 2361-5.
(16.) Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467-520.
(17.) Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al. Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009;92(5): 1586-93.
(18.) Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010;93(3):855-64.
(19.) Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA. The predictive value of circulating anti-Mullerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. J Clin Endocrinol Metab. 2013;98(10):4170-5.
(20.) La Marca A, Broekmans F, Volpe A, Fauser B, Macklon N. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod. 2009;24 (9):2264-75.
(21.) Akpinar F, Dilbaz B, Cirik DA, Yilmaz S, Kiykac S, Karahanoglu E, et al. The significance of anthropometric and endocrine parameters in ovulation induction with clomiphene citrate in women with polycystic ovary syndrome. Saudi Med J. 2016;37 (11):1272-5.
(22.) Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122 (1-3):42-52.
Garima Sachdeva (1*), Shalini Gainder (1), Vanita Suri (1), Naresh Sachdeva (2), Seema Chopra (1)
(1)- Department of Obstetrics and Gynaecology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
(2)- Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
(*) Corresponding Author: Garima Sachdeva, House No 201, Top Floor, Dr Mukherjee Nagar, Delhi-110009, India
Received: Jan. 19, 2019
Accepted: Apr. 14, 2019
Table 1. Baseline mean distribution in the clomiphene sensitive and clomiphene resistant groups and respective p-values Parameters Overall Clomiphene resistant (MEAN[+ or -]SD) (MEAN[+ or -]SD) (N=164) (N=88) Age in years 27.98[+ or -]3.739 27.99[+ or -]3.97 BMI (1) in kg/m (2) 26.077[+ or -]4.306 27.12[+ or -]4.16 Waist circumference in 33.63[+ or -]3.72 34.28[+ or -]3.37 inches Waist-hip ratio 0.88[+ or -]0.044 0.89[+ or -]0.04 Ferriman Gallwey score 13.98[+ or -]3.75 16.11[+ or -]2.87 Testosterone (nmol/l) 2.74[+ or -]1.28 3.30[+ or -]1.39 Androstenedione (ng/ml) 2.97[+ or -]1.36 3.54[+ or -]1.53 OGTT (2)- FASTING (mg/dl) 90.14[+ or -]13.07 92.65[+ or -]14.79 OGTT (2)- 1 HOUR (mg/dl) 148.02[+ or -]35.22 158.33[+ or -]36.05 OGTT (2)- 2 HOUR (mg/dl) 130.73[+ or -]29.37 137.57[+ or -]29.94 Fastingi (mIU/L) 11.89[+ or -]6.83 14.68[+ or -]6.62 HOMA-IR (3) 2.73[+ or -]1.81 3.43[+ or -]1.85 Serum triglycerides (mg/dl) 133.11[+ or -]50.91 146.35[+ or -]60.93 Serum cholesterol (mg/dl) 171.12[+ or -]43.01 190.66[+ or -]37.00 LDL (4) (mg/dl) 110.55[+ or -]0.06 118.82[+ or -]25.26 HDL (5) (mg/dl) 47.98[+ or -]9.67 44.41[+ or -]8.08 AMH (6) (ng/ml) 10.58[+ or -]5.00 12.22[+ or -]5.62 Mean ovarian volume in 12.52[+ or -]3.07 13.65[+ or -]3.26 cm (3) Mean AFC (7) 11.81[+ or -]3.17 13.19[+ or -]3.07 Baseline LH (8) (IU/l) 13.53[+ or -]7.42 14.81[+ or -]8.05 Baseline FSH (9) (IU/l) 5.84[+ or -]2.50 6.02[+ or -]2.72 LH (8)-FSH (9) ratio 2.48[+ or -]1.18 2.66[+ or -]1.22 17 OHP (10) (ng/dl) 1.38[+ or -]0.77 1.49[+ or -]0.8 Parameters Clomiphene sensitive p-value (MEAN[+ or -]SD) (N=76) Age in years 27.97[+ or -]3.48 0.980 BMI (1) in kg/m (2) 24.88[+ or -]4.19 0.001 Waist circumference in inches 32.89[+ or -]3.98 0.017 Waist-hip ratio 0.87[+ or -]0.05 0.008 Ferriman Gallwey score 11.20[+ or -]3.30 0.0001 Testosterone (nmol/l) 2.08[+ or -]0.735 0.0001 Androstenedione (ng/ml) 2.31[+ or -]0.723 0.0001 OGTT (2)- FASTING (mg/dl) 87.24[+ or -]10.08 0.008 OGTT (2)- 1 HOUR (mg/dl) 136.08[+ or -]30.325 0.0001 OGTT (2)- 2 HOUR (mg/dl) 122.82[+ or -]26.67 0.001 Fastingi (mIU/L) 8.65[+ or -]5.55 0.0001 HOMA-IR (3) 1.92[+ or -]1.39 0.0001 Serum triglycerides (mg/dl) 117.19[+ or -]29.71 0.0001 Serum cholesterol (mg/dl) 148.48[+ or -]38.28 0.0001 LDL (4) (mg/dl) 100.97[+ or -]18.31 0.0001 HDL (5) (mg/dl) 52.12[+ or -]9.76 0.0001 AMH (6) (ng/ml) 8.69[+ or -]3.30 0.0001 Mean ovarian volume in cm (3) 11.21[+ or -]2.23 0.001 Mean AFC (7) 10.21[+ or -]2.47 0.000 Baseline LH (8) (IU/l) 12.04[+ or -]6.34 0.007 Baseline FSH (9) (IU/l) 5.64[+ or -]2.22 0.241 LH (8)-FSH (9) ratio 2.27[+ or -]1.11 0.035 17 OHP (10) (ng/dl) 1.26[+ or -]0.7 0.062 (1)-BMI- Body Mass Index, (2)- OGTT- Oral Glucose Tolerance Test, (3)- HOMAIR-Homeostatic Model Assessment Insulin Resistance, (4)-LDL- Low Density Glycoprotein, (5)-HDL- High Density Glycoprotein, (6)- AMH- Anti Mullerian Hormone, (7)-AFC-Antral Follicle Count, (8)-LH- Luteinizing Hormone, (9)-FSH- Follicle Stimulating Hormone, (10)-17OHP- 17-Hydroxyprogesterone Table 2. Univariate regression analysis to predict the response to clomiphene using clinical, metabolic, hormonal and ultra-sonographic findings Variables in the equation S.E. p-value Odd-ratio 95% C.I. (Standard for EXP(B) error) Lower Upper BMI (1) 0.041 0.001 1.140 1.053 1.235 Waist circumference 0.045 0.019 1.111 1.018 1.213 Ferriman Gallwey score 0.071 0.0001 1.628 1.417 1.870 OGTT (2)- fasting 0.013 0.009 1.034 1.008 1.061 OGTT (2)- 1 hr 0.005 0.0001 1.020 1.010 1.030 OGTT (2)- 2 hr 0.006 0.002 1.018 1.007 1.030 HOMA-IR (3) 0.121 0.0001 1.819 1.434 2.307 LDL (4) 0.008 0.0001 1.038 1.021 1.056 HDL (5) 0.022 0.0001 .901 .863 .940 Serum triglyceride 0.004 0.001 1.015 1.006 1.023 Serum cholesterol 0.005 0.0001 1.030 1.020 1.041 Serum androstenedione 0.227 0.0001 3.100 1.986 4.839 AMH (6) 0.042 0.0001 1.190 1.097 1.291 Ovarian volume 0.065 0.0001 1.352 1.190 1.536 AFC (7) 0.060 0.0001 1.244 1.106 1.399 LH (8)-FSH (9) ratio 0.140 0.037 1.339 1.017 1.762 (1)-BMI- Body Mass Index, (2)- OGTT- Oral Glucose Tolerance Test, (3)- HOMAIR-Homeostatic Model Assessment Insulin Resistance, (4)-LDL- Low Density Glycoprotein, (5)-HDL- High Density Glycoprotein, (6)- AMH- Anti Mullerian Hormone, (7)-AFC- Antral Follicle Count, (8)-LH- Luteinizing Hormone, (9)-FSH- Follicle Stimulating Hormone Table 3. Multivariate regression analysis to predict the response to clomiphene using clinical, metabolic, hormonal and ultra-sonographic findings S.E. p-value Odd-ratio 95% C.I. for EXP(B) Lower Upper BMI (1) in kg/m (2) 0.095 0.850 1.018 0.846 1.226 Waist circumference 0.115 0.492 0.924 0.737 1.158 Ferriman Gallwey score 0.113 0.0001 1.564 1.252 1.953 Fasting blood sugar 0.029 0.272 0.969 0.915 1.025 HOMA IR (3) 0.236 0.181 1.372 0.864 2.180 LDL (4) 0.023 0.932 1.002 0.957 1.049 HDL (5) 0.041 0.002 0.879 0.810 0.953 Serum triglyceride 0.007 0.837 0.999 0.986 1.012 Cholesterol 0.016 0.021 1.036 1.005 1.068 Fatty liver present/absent 0.673 0.682 0.759 0.203 2.839 Serum androstenedione 0.417 0.047 2.295 1.013 5.200 AMH (6) 0.081 0.322 1.083 0.925 1.269 Ovarian volume 0.116 0.237 1.147 0.914 1.440 AFC (7) 0.115 0.056 1.246 0.994 1.562 LH (8): FSH (9) ratio 0.288 0.060 1.720 0.978 3.024 Table 4. Predictors of non-response to clomiphene citrate AUC (*) P-VALUE Cut-Value Sensitivity Weight in kg 0.613 0.013 61.5 0.568 BMI (1) in kg/m (2) 0.65 0.001 25.950 0.580 Waist circumference 0.623 0.007 33.750 0.602 Waist-hip ratio 0.624 0.006 0.885 0.580 Ferriman Gallway score 0.871 0.000 15.000 0.739 Serum androstenedione 0.763 0.000 2.480 0.682 Testosterone 0.784 0.000 2.41 0.705 Serum triglyceride 0.658 0.000 126.295 0.614 Cholesterol 0.784 0.000 168.465 0.705 LDL (4) 0.722 0.000 100.430 0.739 HDL (5) 0.732 0.000 48.320 0.671 OGTT (2)- fasting 0.605 0.020 88.500 0.580 OGTT (2)- 1 hr 0.679 0.000 145.500 0.625 OGTT (2)- 2 hr 0.646 0.001 129.500 0.602 Fasting insulin 0.759 0.000 10.77 0.67 HOMAIR (3) 0.757 0.000 2.215 0.659 Mean ovarian volume 0.755 0.000 11.785 0.739 Mean AFC (7) 0.779 0.000 11.75 0.739 AMH (6) 0.707 0.000 9.430 0.682 Baseline LH (8) 0.622 0.007 12.22 0.602 LH (8): FSH (9) ratio 0.605 0.02 2.240 0.602 Specificity Weight in kg 0.526 BMI (1) in kg/m (2) 0.579 Waist circumference 0.579 Waist-hip ratio 0.671 Ferriman Gallway score 0.868 Serum androstenedione 0.684 Testosterone 0.724 Serum triglyceride 0.645 Cholesterol 0.711 LDL (4) 0.737 HDL (5) 0.670 OGTT (2)- fasting 0.605 OGTT (2)- 1 hr 0.632 OGTT (2)- 2 hr 0.605 Fasting insulin 0.67 HOMAIR (3) 0.658 Mean ovarian volume 0.724 Mean AFC (7) 0.737 AMH (6) 0.671 Baseline LH (8) 0.592 LH (8): FSH (9) ratio 0.605 AUC (*)- Area Under the Curve for Roc
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Sachdeva, Garima; Gainder, Shalini; Suri, Vanita; Sachdeva, Naresh; Chopra, Seema|
|Publication:||Journal of Reproduction and Infertility|
|Article Type:||Clinical report|
|Date:||Jul 1, 2019|
|Previous Article:||Association Between Sex Steroids and Oxidative Status with Vitamin D Levels in Follicular Fluid of Non-obese PCOS and Healthy Women.|
|Next Article:||Impact of Genetic Variants in Estrogen Receptor-[beta] Gene in the Etiology of Uterine Leiomyomas.|